Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. - Wikidata - awgldk - TriplyDB

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54225327

about

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Recent advances in understanding myelofibrosis and essential thrombocythemia Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization.Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and T Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.Calreticulin exon 9 mutations in myeloproliferative neoplasms.Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.The molecular basis of myeloid malignancies.Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.CD133 marks a stem cell population that drives human primary myelofibrosis.Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Visualizing tumor evolution with the fishplot package for R Myeloproliferative Neoplasms in Children Effect of mutation order on myeloproliferative neoplasms.Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas.Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

P2860

Q26738514-E45006DD-27E8-4EC4-A2A1-5CB79CBA3297 Q26748543-BF166718-DAB6-452A-80A8-8603373534D7 Q26750696-9938BD35-524C-402A-AA9B-E2B4B690161D Q26766319-F2EE4F7D-F757-481A-9296-763DB36E79F1 Q26774212-FA934BC1-C8DF-46BE-B10B-A29EBFEF40C7 Q26775996-9C0BD8DF-DD24-4602-B26A-735E9DB59167 Q26779929-758665BE-CE7D-4A25-9F4B-9A2BA8B8B183 Q26779960-EFCC814D-57E9-4365-8A63-CCA9A895750E Q26799790-D6F92A5A-5C69-4F75-8898-FF4A7B92E671 Q26851894-080E6062-1BBE-4FCE-B98A-748A4797A8F1 Q27853043-CAB6F529-548A-4103-B5A6-D81A82B3FE95 Q27853179-A05AFD94-CE32-4CD7-872B-FBE18C0B3688 Q28073296-EC2837FE-DE04-44C4-8010-3B0D50DC6809 Q28076096-6F951197-4F7B-40C9-90EA-CF361399C06A Q28084727-3714A25E-7AA4-4AB3-AF9D-9FDC1674EC35 Q30235926-40E7E92D-CDF6-4014-AA66-F2CC0D532720 Q30410213-33769681-FBF8-41C9-806E-B001B54C722B Q31159627-B675BBC6-9B8D-47E7-9AA1-7518758A7F1A Q33416223-B19F920D-FD34-49FF-B4D9-29FD62E83710 Q33417217-E5DDA1DF-B102-4C52-B8E4-08C4A9F8520F Q33572605-F30E29C2-9ED1-4438-A901-8FAE0D8E53A1 Q33595912-EE60C8FD-1DE1-4003-B9E5-1EBAAF9AD0C5 Q33779135-6193DF8E-13E0-4036-8833-BBB3C87D4B9A Q34375134-AE2A18BA-5B67-4862-B8C0-FA711DEEABC4 Q34467863-65282AEB-5BF3-4247-9EB7-2B3A8931C213 Q34471813-CE4EC081-DF24-4F92-A6F7-9E14EF1F043F Q34749671-31CEE260-D91E-49EC-A2BD-144D828AF959 Q34876785-3B4B029C-9416-4606-9CA7-742B4CDD450B Q35103708-C641BF17-29F7-478A-A02F-A27CCCD9C794 Q35217865-2D409912-6B94-4565-B2A0-728141491DB0 Q35610140-386405F7-765B-4FEC-89AC-EA9038947E45 Q35669866-9546843E-E6A4-4E29-A910-669EFE5B803E Q35800819-F3767FFE-C477-46DD-9F60-3070AFF91542 Q36169641-62DC26CB-51BF-44BB-9962-F600EF40BD00 Q36184539-4452830B-823F-4796-ADAD-4E38075EB2BA Q36305041-93488A12-91A8-4A4E-8770-E0B39CFF7C61 Q36320344-536711A6-A018-44D7-89E5-18B8C22C7136 Q36541323-1C7DB003-5082-4D4D-ADF0-1A3F272DB21E Q36685471-5824910A-E04F-4616-B38D-CDC802A455E3 Q37035925-F470C081-4371-41A5-8C5C-92E9FB8F16E1

P2860

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54225327

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Clonal evolution and clinical ...... myeloproliferative neoplasms.

@en

Clonal evolution and clinical ...... myeloproliferative neoplasms.

@nl

type

label

Clonal evolution and clinical ...... myeloproliferative neoplasms.

@en

Clonal evolution and clinical ...... myeloproliferative neoplasms.

@nl

prefLabel

Clonal evolution and clinical ...... myeloproliferative neoplasms.

@en

Clonal evolution and clinical ...... myeloproliferative neoplasms.

@nl

P1433

Q54225327-5543B52E-98C2-4ABF-AE86-2AF4343FF7DA

P1476

Q54225327-E94F42FE-FF84-4386-ABB8-33FC3D8F72DF

P2093

Q54225327-12987B18-0D3E-43A1-B03F-F256FE94F57E

Q54225327-1666F066-0C10-4842-BE77-204D149D8128

Q54225327-28DD00E4-A6F9-4E4E-ACE6-2D97229AA223

Q54225327-393E8EB1-0C86-483A-B984-B3066A2008C5

Q54225327-3D84AE58-631F-49D9-897C-3E202B4B7756

Q54225327-6B0B844E-40D3-4F3D-8293-A6C6F80D17E6

Q54225327-AF37DDFE-9F29-4246-957F-A7F6A7F55DBE

Q54225327-C2B1BC6D-7688-4013-92A1-1B65D843C618

Q54225327-DD54D781-C7AA-4BA6-9AC3-D359B1222F49

Q54225327-FA2B0D1E-77BC-45E0-88B0-0A421D5718CB

P304

Q54225327-F7DB893A-6369-4D4D-928B-BB648A994EF9

P31

Q54225327-06DF1462-9822-43C4-9DD9-AC32B16D6912

P356

Q54225327-17DE13AC-667D-4D07-B8F7-2FFF840826C1

P407

Q54225327-935A92A1-EB9A-44CF-960E-59C116F828D3

P433

Q54225327-67D079BD-14E4-40D3-8E98-0E26BBB66A1E

P478

Q54225327-7C2E4FCB-953A-4CA8-B11C-CCBA9D3C4827

P50

Q54225327-80D3258E-AC8A-416E-802B-C716C2299CC8

Q54225327-A3554F10-A7B9-47E4-89D3-AA5DFA545C34

Q54225327-B37D3AA7-38E2-491D-BA29-9BFE6700635F

P577

Q54225327-253E6570-C407-48C0-92DF-B8EDB06263F9

P698

Q54225327-527D8DFC-54ED-4636-A3F4-E3A6FD64218D

P356

BLOOD-2013-11-537167

P1433

P1476

Clonal evolution and clinical ...... myeloproliferative neoplasms.

@en

P2093

Axel Karow

http://www.w3.org/2001/XMLSchema#string

Christian Beisel

http://www.w3.org/2001/XMLSchema#string

Hui Hao-Shen

http://www.w3.org/2001/XMLSchema#string

Ina Nissen

http://www.w3.org/2001/XMLSchema#string

Martin Stern

http://www.w3.org/2001/XMLSchema#string

Pontus Lundberg

http://www.w3.org/2001/XMLSchema#string

Radek C Skoda

http://www.w3.org/2001/XMLSchema#string

Renate Looser

http://www.w3.org/2001/XMLSchema#string

Sabine Girsberger

http://www.w3.org/2001/XMLSchema#string

Thomas Lehmann

http://www.w3.org/2001/XMLSchema#string

P304

2220-2228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-11-537167

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Robert Kralovics

Jakob R. Passweg

P577

2014-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24478400

http://www.w3.org/2001/XMLSchema#string